Ceritinib in the treatment of ALK-positive patients with nonsmall-cell lung cancer

Ceritinib in the treatment of ALK-positive patients with nonsmall-cell lung cancer

Ceritinib is the second ALK tyrosine kinase inhibitor after crizotinib, registered in the Russian Federation for the treatment of ALKpositive patients with non-small cell lung cancer (NSCLC). Later alectinib was registered. Thus, we have the opportunity, firstly, to continue targeted therapy with se...

Full description

Saved in:
Bibliographic Details
Published in:Medicinskij sovet no. 10; pp. 37 - 41
Main Authors: Laktionov, K. K., Reutova, E. V.
Format: Journal Article
Language:English
Russian
Published: Remedium Group LLC 24-06-2019
Subjects:
alk
ceritinib
non-small-cell lung cancer
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ceritinib is the second ALK tyrosine kinase inhibitor after crizotinib, registered in the Russian Federation for the treatment of ALKpositive patients with non-small cell lung cancer (NSCLC). Later alectinib was registered. Thus, we have the opportunity, firstly, to continue targeted therapy with second-generation drugs after progression on crizotinib, and secondly, the appointment of more active drugs in the first line provides the best results of treatment.
ISSN:2079-701X
2658-5790
DOI:10.21518/2079-701X-2019-10-37-41